Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009956 | 0.82 | HDAC3 (0.36) | HDAC3HDAC6BMP1KCNA5CYP11B1 | |
| SCHEMBL6978240 | 0.80 | CYP11B1 (0.37) | HDAC3HDAC6BMP1KCNA5CYP11B1 | |
| SCHEMBL1765841 | 0.79 | CYP11B1 (0.40) | HDAC3HDAC6BMP1KCNA5CYP11B1 | |
| SCHEMBL5643534 | 0.76 | NOS1 (0.47) | BMP1 | |
| SCHEMBL4957722 | 0.76 | NOS1 (0.47) | BMP1 | |
| SCHEMBL27089283 | 0.74 | SMN1; SMN2 (0.36) | HDAC3HDAC6BMP1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL3149192 | 0.73 | CYP11B1 (0.38) | HDAC3HDAC6BMP1CYP11B1CYP11B2 | |
| SCHEMBL8481796 | 0.73 | CYP11B1 (0.40) | HDAC3HDAC6BMP1CYP11B1CYP11B2 | |
| SCHEMBL6613495 | 0.73 | HDAC3 (0.40) | HDAC3HDAC6BMP1CYP11B1CYP11B2 | |
| SCHEMBL9239487 | 0.73 | CYP11B1 (0.37) | HDAC3HDAC6BMP1KCNA5CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| CN-1445226-A | New cornpound derivated from quinazoline, itd preparation method and medicinal composite containig them | ADIR (FR) | 2003-10-01 | — | — | CN | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | HDAC3 1100/4885HDAC6 307/4885BMP1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.